written on 05.06.2014

Boehringer's lung drug gets a boost from European regulators

TAGS: ,

Boehringer Ingelheim persuaded EU officials to put its lung-disease drug nintedanib on its development fast track, speeding its path to market as a treatment for idiopathic pulmonary fibrosis.